Cargando…
Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: A multicentre, double-blind, and randomised controlled trial
BACKGROUND: As of September 17, 2021, coronavirus disease 2019 (COVID-19) has infected more than 226 million people in a worldwide pandemic, with conservative estimates suggesting that there are more than 204 million convalescent patients with COVID-19. Previous studies have indicated that patients...
Autores principales: | Chen, Yuqin, Liu, Chunli, Wang, Tingping, Qi, Jingjing, Jia, Xiaoqing, Zeng, Xiansheng, Bai, Jianling, Lu, Wenju, Deng, Yu, Zhong, Bihua, He, Wenjun, Xing, Yue, Lian, Zhan, Zhou, Haohao, Yan, Junping, Yang, Xuejiao, Yu, Hao, Zhou, Jiawei, Zhou, Dansha, Qiu, Lixia, Zhong, Nanshan, Wang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575540/ https://www.ncbi.nlm.nih.gov/pubmed/34763045 http://dx.doi.org/10.1016/j.jep.2021.114830 |
Ejemplares similares
-
Bufei huoxue capsules in the management of convalescent COVID-19 infection: study protocol for a multicenter, double-blind, and randomized controlled trial
por: Chen, Yuqin, et al.
Publicado: (2021) -
Bufei Huoxue Capsule Attenuates PM2.5-Induced Pulmonary Inflammation in Mice
por: Jing, Yue, et al.
Publicado: (2017) -
Systematic Pharmacology-Based Strategy to Explore the Mechanism of Bufei Huoxue Capsule in the Treatment of Chronic Obstructive Pulmonary Disease
por: Shi, Liangtian, et al.
Publicado: (2022) -
Exploring the Ferroptosis Mechanism of Zhilong Huoxue Tongyu Capsule for the Treatment of Intracerebral Hemorrhage Based on Network Pharmacology and In Vivo Validation
por: Wang, Lixia, et al.
Publicado: (2022) -
Investigation on the mechanisms of guiqi huoxue capsule for treating cervical spondylosis based on network pharmacology and molecular docking
por: Liu, Yingying, et al.
Publicado: (2021)